Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 91198

3 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
November 22, 2022
Product types
Drug
Classifications
Class II
Statuses
Terminated
Recalling firm wording
Fresenius Kabi USA, LLC

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

3 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 3

Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 125 mg per 50 mL (2.5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-461-01), packaged in 25 Multiple Dose Vials per tray (NDC 63323-461-57), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

D-0127-2023
Recall number
D-0127-2023
Initiated
November 22, 2022
Classification
Class II
Status
Terminated
Recalling firm
Fresenius Kabi USA, LLC
Quantity
40,375 vials

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Code information

Batch #: 6128061, exp 03/2024; 6128663, 6128664, exp 05/2024

Distribution pattern

Nationwide in the USA

drug · product 2 of 3

Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.5%, 250 mg per 50 mL (5 mg per mL), 50 mL Multiple Dose Vial (NDC 63323-463-01), packaged in 25 Multiple Dose Vials per tray (NDC 63323-463-57), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

D-0128-2023
Recall number
D-0128-2023
Initiated
November 22, 2022
Classification
Class II
Status
Terminated
Recalling firm
Fresenius Kabi USA, LLC
Quantity
40,025 vials

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Code information

Batch #: 6128399, 6128400, 6128401, exp 04/2024

Distribution pattern

Nationwide in the USA

drug · product 3 of 3

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose Vials per tray (NDC 63323-468-17), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

D-0129-2023
Recall number
D-0129-2023
Initiated
November 22, 2022
Classification
Class II
Status
Terminated
Recalling firm
Fresenius Kabi USA, LLC
Quantity
31,600 vials

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0
Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Code information

Batch #: 6128800, exp 12/2023

Distribution pattern

Nationwide in the USA

Field note

Send feedback

We'll only use this to respond to your feedback.